Oncodermatology, Claudius Regaud Institute and University Cancer Institute, Toulouse Oncopole - 1 Avenue Irène Joliot-Curie 31059, Toulouse Cedex 9, France.
UOC Dermatologia, Fondazione Policlinico Universitario A.Gemelli-IRCCS, L.go Agostino Gemelli 8, 00168 Rome, Italy.
Ann Dermatol Venereol. 2023 Sep;150(3):208-212. doi: 10.1016/j.annder.2022.11.013. Epub 2023 Aug 14.
Cyclin-dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) have revolutionized the treatment of metastatic breast carcinoma. They currently form the first-line treatment, in combination with endocrine agents, for the management of locally advanced or metastatic hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the largest subtype of breast carcinoma. CDK 4/6 inhibitors have shown comparable efficacy outcomes with predictable and manageable adverse events. In this setting, dermatologic toxicity appears to be relatively frequent, accounting for up to 15% of all reported adverse events. It is usually mild to moderate in intensity and does not normally constitute a dose-limiting toxicity. The range of dermatologic adverse events includes both non-specific entities (maculopapular rash, pruritus, alopecia) and more characteristic toxicities related to CDK4/6 inhibitors, such as vitiligo-like lesions or cutaneous lupus erythematosus. Finally, more severe or life-threatening skin reactions can occasionally occur. The main dermatologic manifestations associated with CDK4/6 inhibitors, as well as management thereof, are described in this comprehensive review.
细胞周期蛋白依赖性激酶 (CDK) 4/6 抑制剂（帕博西利、瑞博西利和阿贝西利）彻底改变了转移性乳腺癌的治疗方法。目前，它们与内分泌治疗药物联合，作为激素受体阳性 (HR+）、人表皮生长因子受体 2 阴性 (HER2-) 乳腺癌的一线治疗方法，这是乳腺癌的最大亚型。CDK 4/6 抑制剂具有可预测和可管理的不良反应，疗效相当。在这种情况下，皮肤毒性似乎较为常见，占所有报告不良事件的 15%左右。其严重程度通常为轻至中度，通常不会成为剂量限制毒性。皮肤不良事件的范围包括非特异性实体（斑丘疹、瘙痒、脱发）和与 CDK4/6 抑制剂相关的更具特征性的毒性，如白癜风样病变或盘状红斑狼疮样皮疹。最后，偶尔会出现更严重或危及生命的皮肤反应。本文全面回顾了与 CDK4/6 抑制剂相关的主要皮肤表现及其处理方法。
